Skip to main content
Retour
Watch Compare

Outlook Therapeutics, Inc.

Qualité des données : 100%
OTLK
Nasdaq Manufacturing Chemicals
0,22 €
▼ 0,03 € (-10,52%)
Cap. Boursière: 23,41 M
Prix
0,22 €
Cap. Boursière
23,41 M
Fourchette du Jour
0,21 € — 0,25 €
Fourchette 52 Semaines
0,16 € — 3,39 €
Volume
4 486 174
Ouverture 0,25 €
Moyenne 50J / 200J
0,38 €
41,70% below
Moyenne 50J / 200J
1,27 €
82,34% below

Quick Summary

Points Clés

Negative free cash flow of -55,80 M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
N/A
ROICN/A
Net Margin-7276,84%
Op. Margin-4169,60%

Sécurité

Debt / Equity
N/A
Current Ratio0,35
Interest Coverage-177,52

Valorisation

PE (TTM)
-0,23
Au-dessus de la moyenne du secteur (-1,48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -0,2 -1,5
P/B — 1,6
ROE % — -53,4
Net Margin % -7276,8 -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 1,41 M Net Income (TTM) -102,86 M
ROE N/A ROA -506,33%
Gross Margin -83,50% Operating Margin -4169,60%
Net Margin -7276,84% Free Cash Flow (TTM) -55,80 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,35
Interest Coverage -177,52 Asset Turnover 0,07
Working Capital -31,89 M Tangible Book Value -38,55 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,23 Forward P/E N/A
P/B Ratio N/A P/S Ratio 16,56
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -238,34%
Market Cap 23,41 M Enterprise Value 14,74 M
Per Share
EPS (Diluted TTM) -2,89 Revenue / Share 0,01
FCF / Share -0,53 OCF / Share -0,53
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 54,25%
SBC-Adj. FCF -63,76 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1,41 M — — — —
Net Income -62,42 M -75,37 M -58,98 M -66,05 M -53,16 M
EPS (Diluted) -1,79 -4,06 -0,24 -0,31 -0,35
Gross Profit 57 205,0 — — — —
Operating Income -67,06 M -71,70 M -53,13 M -63,07 M -51,73 M
EBITDA — — — — —
R&D Expenses 27,18 M 41,76 M 26,45 M 42,33 M 38,96 M
SG&A Expenses 39,94 M — — — —
D&A 117 052,0 113 859,0 44 188,0 204 694,0 262 140,0
Interest Expense -283 128,0 3,16 M -1,56 M -1,49 M -936 127,0
Income Tax -1,55 M 2 800,0 2 800,0 2 800,0 2 000,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 18,58 M 28,82 M 32,30 M 28,53 M 22,81 M
Total Liabilities 50,77 M 101,90 M 46,74 M 19,79 M 18,20 M
Shareholders' Equity -32,19 M -73,08 M -14,44 M 8,74 M 4,61 M
Total Debt — — — — —
Cash & Equivalents 8,08 M 14,93 M 23,39 M 17,40 M 14,48 M
Current Assets 17,39 M 27,42 M 30,98 M 27,52 M 21,51 M
Current Liabilities 45,81 M 42,55 M 46,73 M 19,73 M 6,75 M